You are here: Industry Insights > Merck

News List

Merck Supports Jenner Institute to Reach First Milestone in Covid-19 Vaccine Manufacturing prnasia
April 14, 2020
Merck, a leading science and technology company, and The Jenner Institute today announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
AstraZeneca, Merck secure FDA nod for Koselugo to treat paediatric patients with NF1 genetic disorder pharmaceutical-business-review
April 14, 2020
AstraZeneca and Merck have secured approval from the US Food and Drug Administration (FDA) for Koselugo (selumetinib) .
Merck awarded second US patent for CRISPR Gene-Editing Technology expresspharma
April 09, 2020
Merck announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology.
Pharma programmes for employees to volunteer in fight against COVID-19 europeanpharmaceuticalreview
April 07, 2020
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
Merck’s vericiguat meets primary endpoint in VICTORIA trial pharmaceutical-business-review
April 01, 2020
Merck said that its orally administered soluble guanylate cyclase (sGC) stimulator vericiguat met the primary efficacy endpoint in the phase 3 VICTORIA trial in heart failure patients.
TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations prnasia
March 25, 2020
Merck, a leading science and technology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved TEPMETKO®* (tepotinib) for the treatment of patients with unresectable, advanced or recurrent non-small cell lung
Merck signs drug development deal with Dragonfly Therapeutics pharmaceutical-technology
March 23, 2020
Merck (MSD) has partnered with Dragonfly Therapeutics for the discovery, development and commercialisation of drug candidates across oncology, infectious disease and immune disorder indications.
Merck, Pfizer terminate Bavencio head and neck cancer trial pharmatimes
March 17, 2020
Merck KGaA and Pfizer have decided to stop their Phase III JAVELIN study testing Bavencio (avelumab) as a potential treatment for certain patients with advanced head and neck cancer.
Merck and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study prnasia
March 14, 2020
A detailed analysis of the Phase III JAVELIN Head and Neck 100 study is being conducted and study findings will be shared with the scientific community.
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents pharmaceutical-business-review
March 06, 2020
Merck, known as MSD outside the United States and Canada, and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, announced the publication of research on the discovery ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page